Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 12/20 | 0.46 |
| ▸ | DLK1 | P80370 | 1/20 | 0.46 |
| ▸ | IDH1 | O75874 | 3/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21143985 | 0.92 | MAP3K12 (0.47) | MAP3K12DLK1IDH1EPHX2SYK | |
| SCHEMBL19687007 | 0.91 | IDH1 (0.39) | MAP3K12DLK1IDH1HTR1ADRD2 | |
| SCHEMBL21143643 | 0.88 | IDH1 (0.48) | MAP3K12DLK1IDH1SYK | |
| SCHEMBL19687019 | 0.84 | MAP3K12 (0.46) | MAP3K12DLK1IDH1EPHX2SYK | |
| SCHEMBL19687145 | 0.82 | IDH1 (0.45) | IDH1 | |
| SCHEMBL31127365 | 0.82 | IDH1 (0.45) | IDH1 | |
| SCHEMBL19686279 | 0.80 | IDH1 (0.51) | IDH1 | |
| SCHEMBL31127138 | 0.80 | IDH1 (0.50) | MAP3K12IDH1 | |
| SCHEMBL19686734 | 0.80 | IDH1 (0.50) | MAP3K12IDH1 | |
| SCHEMBL19686275 | 0.79 | IDH1 (0.49) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| WO-2017139697-A9 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | SYNLOGIC, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | MAP3K12 369/4885DLK1 4046/4885IDH1 3017/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | MAP3K12 369/4885DLK1 4046/4885IDH1 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.